Sarepta stock catapulted Thursday after the company announced a restructuring that includes 500 layoffs in the wake of two patient deaths.

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...

Just how many employees is Sarepta Therapeutics laying off? And why did the FDA reject Ultragenyx's rare disease drug over ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta Therapeutics is facing a challenging period after the deaths of two patients who received its Columbus-invented gene ...

The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

Stronger-than-expected economic support from consumers reinforces the case for the Federal Reserve to stay in its holding ...

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...